Price
No data yet.
Social Signal Score
Revenue
$14.42B+7.86%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Vas Narasimhan
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 75,267
- Beta
- 0.46
- Country
- CH
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 3.53
Financials
Revenue
$14.42B+7.9%Net Income
$3.27B+18.4%EBITDA
$5.94B+21.5%Free Cash Flow
$5.57B+26.9%EPS (diluted)
$1.71+40.2%Shares Outstanding (diluted)
1.91B-15.1%Operating Expenses
$6.00BCash & Debt
$7.69BReturn of Capital
$4.06BRevenue by Segment (annual)
$43.27BDividend per Share
$4.74Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $54.81B | $14.06B | $7.25 |
| 2024 | $51.72B | $11.94B | $5.92 |
| 2023 | $46.66B | $14.85B | $7.15 |
| 2022 | $43.46B | $6.96B | $3.19 |
| 2021 | $43.97B | $24.02B | $10.71 |
| 2020 | $49.90B | $8.07B | $3.54 |
| 2019 | $48.68B | $11.73B | $3.12 |
| 2018 | $46.10B | $12.61B | $5.44 |
| 2017 | $43.40B | $7.70B | $3.28 |
| 2016 | $49.44B | $6.71B | $2.82 |
| 2015 | $50.39B | $17.78B | $7.40 |
| 2014 | $53.63B | $10.21B | $4.21 |
| 2013 | $52.72B | $9.18B | $3.76 |
| 2012 | $51.97B | $9.27B | $3.93 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from NVS's reported EPS growth of 4.8% a year over 13 years.
- EPS in 5 years
- $9.16
- Implied price
- $174.12
- Return from $158.79
- 1.9% a year
To earn 15.0% a year on these assumptions you'd need to buy at $86.57 — -45.5% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 13 | 16 | 19 | 22 | 25 |
|---|---|---|---|---|---|
| -5.2% | -14.6% | -11.0% | -7.9% | -5.1% | -2.7% |
| -0.2% | -10.1% | -6.3% | -3.0% | -0.1% | 2.5% |
| 4.8% | -5.6% | -1.6% | 1.9% | 4.9% | 7.6% |
| 9.8% | -1.1% | 3.1% | 6.7% | 9.9% | 12.7% |
| 14.8% | 3.4% | 7.8% | 11.6% | 14.9% | 17.9% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
100Social Signal Score
Mentions (1)
- News247wallst.com·6h ago·Neutral
Why Novartis, Lilly, and Bristol Myers Are Eyeing This Clinical-Stage Cancer Play Aktis Oncology (NASDAQ:AKTS) closed at $25.00 on August 18, 2026, giving the clinical-stage radiopharmaceutical company a market cap of $1.4 billion.
View source ↗
Earnings
Tue, Oct 27(in 2 months)
Consensus estimate $2.24 per share
Typical surprise +2.0% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Jul 21$2.41 vs $2.17beat
- Tue, Apr 28$1.99 vs $2.11miss
- Wed, Feb 4$2.03 vs $1.99beat
- Tue, Oct 28$2.25 vs $2.26miss
- Thu, Jul 17$2.42 vs $2.38beat
- Tue, Apr 29$2.28 vs $2.12beat
Estimates and results for NVS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.